Chief, Biological Resources Branch, Developmental Therapeutics Program
National Cancer Institute, DCTD, DTP
June 8, 2018
Full Time - Experienced
Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Division of Cancer Treatment & Diagnosis
Developmental Therapeutics Program
Biological Resources Branch
The Developmental Therapeutics Program (DTP), of the NCI, is seeking candidates with an advanced degree in Biology, Microbiology, or equivalent for the position of Branch Chief, Biological Resources Branch (BRB).
The candidate will be a Supervisory Biologist directing the activities of the BRB (https://ncifrederick.cancer.gov/research/brb/) and will collaborate with investigators of the NCI DTP (https://dtp.cancer.gov/). The candidate will manage and coordinate all functional requirements for the branch including preclinical development research, clinical manufacturing and testing of biopharmaceutical products, and related studies pertaining to the extramural work of the BRB. The agents to be developed and manufactured in this program are biopharmaceutical and immunotherapy agents including, but not limited to, recombinant proteins, peptides, vaccines, monoclonal antibodies, genetically modified viruses, bacteria or mammalian cells, immunomodulating agents, cytokines and growth factors, tumor antigens, and nanotechnology-based biopharmaceutical products. The Chief manages and coordinates a system of grants and contracts to discover, investigate, develop and bring to initial clinical trials selected biologics and biopharmaceuticals with the intent of producing a therapeutic affect that alters the biology of cell growth and metastasis.
This is an exploratory ad to gauge interest and a possible candidate pool. A vacancy announcement (VA) to fill the position will be posted on WWW.USAJOBS.GOV at a later date.
Candidates must be U.S. citizens. Compensation for this position is commensurate with the individual’s qualifications and experience as permitted within Federal Government appointments.
Please submit your C.V., a statement of interest, and contact information for three references to Dr. Rosemarie Aurigemma, Developmental Therapeutics Program, National Cancer Institute at email@example.com (phone 240-276-5465).
DHHS, NIH, and NCI are Equal Opportunity Employers.
Internal Number: BRBBC1
About National Cancer Institute, DCTD, DTP
The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. Since its inception in 1955 by Congress, DTP has supported the development of more than 40 US-licensed anti-cancer agents through extensive collaborations with academic, pharmaceutical and biotechnology industries, including Paclitaxel, Romidepsin, Eribulin, Sipuleucel-T, and Dinutuximab (Ch14.18).Today, most of DTP’s drug discovery and development services are available for academic and private researchers through applying for NCI Experimental Therapeutic program (NExT). Under this new framework, DTP continues to help academic and private sectors to overcome financial and technical barriers, particularly through supporting high-risk treatments for rare cancers, and facilitate the movement of promising therapeutic agents from scientists’ bench side to patients’ bed side.